Skip to main content

Table 1 IC50 values of anthraquinone derivatives (compound 1–5) on various skin cancer cells (SK-MEL5 and B16F10) and breast cancer cells (MCF7 and MBA-MD-231)

From: Cytotoxic properties of the anthraquinone derivatives isolated from the roots of Rubia philippinensis

Compounds

IC50 (μM)a

 

SK-MEL-5

B16F10

MCF7

MDA-MB-231

MDCK

1

91.04 ± 1.88

48.68 ± 0.10

65.48 ± 1.10

49.44 ± 0.78

192.34 ± 0.49

2

46.75 ± 1.39

77.88 ± 0.34

79.96 ± 1.14

59.22 ± 0.40

168.76 ± 0.61

3

53.08 ± 0.30

98.79 ± 2.10

49.17 ± 0.85

48.64 ± 0.33

199.32 ± 1.88

4

21.35 ± 0.99

23.71 ± 1.71

15.75 ± 1.00

14.65 ± 1.45

67.89 ± 1.02

5

42.79 ± 1.32

29.48 ± 2.61

24.10 ± 1.06

13.03 ± 0.33

79.01 ± 0.03

Oxaloplatin

14.25 ± 1.02

10.51 ± 0.92

8.59 ± 1.22

7.95 ± 1.92

24.02 ± 1.04

  1. aThe values are mean ± standard deviation. IC50 (concentration inhibiting 50% growth). SK-MEL-5 (human melanoma); B16F10 (murine melanoma); MCF-7 (human breast adenocarcinoma); MDA-MB-231 (human breast adenocarcinoma), MDCK (normal kidney epithelial cells)